BioVector® pHFMDHZ-A Foot-and-Mouth Disease Virus DNA Vaccine Expression Vector / pHFMDHZ-A 口蹄疫病毒DNA疫苗与重组高效表达载体

一 产品基本信息与分子生物学背景

• 载体名称：pHFMDHZ-A。

• 载体分类：哺乳动物细胞真核表达质粒 / 口蹄疫病毒（FMDV）多表位重组DNA疫苗载体。

• 质粒大小：约 5.5 - 6.2 kb（依据克隆的 FMDV 特异性抗原表位或全长 $VP1$ 基因片段的血清型微调）。

• 骨架源起与设计背景（兽医病毒学疫苗标盘）：

  pHFMDHZ-A 是一款在兽医病毒学、现代畜牧业传染病防控以及合成生物学疫苗工程中广泛应用的专用真核表达质粒。其核心骨架主要基于强力的真核表达体系（通常派生自带有高级顺式促表达元件的 pcDNA 系列或 pVAX1 疫苗标准底盘），专为针对口蹄疫病毒（Foot-and-Mouth Disease Virus, FMDV）的 A 型（或融合 O 型等中和表位）进行高水平抗原递呈而设计。

  传统的灭活口蹄疫疫苗存在生产过程中病毒泄漏、热稳定性差以及无法区分免疫动物与自然感染动物（DIVA 缺陷）等安全隐患。pHFMDHZ-A 重组质粒通过在宿主（如猪、牛、羊等偶蹄动物）骨骼肌细胞中直接转录并翻译出 FMDV 的核心中和抗原（如结构蛋白 $VP1$ 或其连续多表位多肽 Poly-epitope），诱导机体产生强烈的体液免疫与细胞免疫应答，是研发新型基因工程核酸疫苗、DNA 载体主次免疫策略（Prime-boost strategy）的经典骨架。

• 核心顺式作用元件与图谱特征：

  • 人巨细胞病毒超强启动子（CMV Promoter）：驱动下游 FMDV 抗原基因在哺乳动物及家畜骨骼肌/树突状细胞中进行不依赖宿主细胞周期的、极其强劲的结构性转录。

  • FMDV A型核心抗原编码夹层（FMDV-A Antigen Cassette）：多克隆位点（MCS）中已原装嵌入或保留用于插入口蹄疫病毒 A 型毒株的核心免疫原片段。它通常包含 $VP1$ 关键环区（G-H Loop）的 B 细胞中和表位与特定的 T 细胞辅助表位串联体。

  • 真核高效翻译与加尾元件：配置了优化的 Kozak 序列（确保核糖体精准锚定并启动翻译）以及典型的牛生长激素聚腺苷酸信号（BGH polyA），可最大化提升 mRNA 在家畜胞内的稳定性和生存期。

  • 大肠杆菌复制与抗性（符合国际疫苗安全标准）：含有 pUC ori 以及 卡那霉素抗性基因（$Kan^R$）（严禁使用氨苄青霉素抗性，以完全符合国际兽药组织和 FDA 关于动物 DNA 疫苗中不得引入内酰胺类抗生素标记的安全红线），专用于前期在 E. coli 中进行大规模、高密度的发酵工程纯化。

二 核心科研价值与兽医临床转化应用

pHFMDHZ-A 质粒在现代动物医学、新型核酸免疫及重大传染病阻断中占据核心一席：

1. 家畜口蹄疫 A 型/多价重组 DNA 疫苗效能评估：

   利用 pHFMDHZ-A 载体直接肌肉注射或通过基因枪（Gene gun）导入猪、牛等靶向目标宿主。质粒被肌细胞或抗原递呈细胞（APC）吞噬后，在体内持续合成 FMDV 病毒样抗原结构，刺激 T、B 淋巴细胞全面激活。通过检测动物血清中的中和抗体效价（Neutralizing antibody titer）以及 IFN-$\gamma$ 等细胞因子的释放水平，评估该 DNA 疫苗在面临强毒株攻击时的真实保护率（Protection rate）。

2. 多表位串联与新型佐剂（Adjuvant）配伍设计：

   科研人员常利用该骨架的 MCS 区域，将 FMDV 的核心中和表位与重组免疫佐剂基因（如家畜 IL-2、IL-6 或粒细胞-巨噬细胞集落刺激因子 GM-CSF）并排串联共表达。这种一体化的分子设计能显著突破传统 DNA 疫苗免疫原性偏弱的瓶颈，成倍提升家畜产生特异性 IgG 抗体的速度和丰度。

3. 反向遗传学与病毒样颗粒（VLPs）体外组装：

   通过将 FMDV 的主要结构蛋白（$VP0$, $VP3$, $VP1$）联合组装入 pHFMDHZ-A 衍生系统中，在哺乳动物细胞（如 BHK-21）内共表达，可促使这些衣壳蛋白在胞内自组装形成不含病毒核酸、却具有高度天然空间构象的病毒样颗粒（Virus-Like Particles, VLPs）。这为开发绝对安全、无传染性、且能完美分辩“免疫与感染”的新一代口蹄疫亚单位工程疫苗提供了精密的反应底盘。

三 实验室大肠克隆、发酵纯化、哺乳动物细胞转染与体内免疫质控标准步骤

1. 质粒在大肠杆菌（E. coli）中的高密度发酵与无毒纯化（制备疫苗级 DNA）

• 转化与平板筛选：将环状 pHFMDHZ-A 质粒转化入常规大肠杆菌高产量菌株（如 DH5$\alpha$ 或 JM109）感受态中。均匀涂布于含有 50 $\mu$g/mL 卡那霉素（Kanamycin）的常规 LB 固体平板上，37 ℃ 培养过夜。

• 高质纯化（绝对关键点：去除内毒素）：

  由于该质粒最终通常需要用于动物活体注射或哺乳动物原代细胞转染，普通的普通质粒提取试剂盒无法满足要求。必须使用去内毒素重组质粒大抽试剂盒（Endotoxin-free Plasmid Maxiprep Kit）。纯化出的疫苗级 DNA 必须满足：浓度 $\ge 1.0\text{ mg/mL}$，纯度 $OD_{260}/OD_{280} = 1.80 - 1.90$，且内毒素（Endotoxin）含量必须 $\lt 0.1\text{ EU/}\mu\text{g}$。内毒素过高会在动物体内引发强烈的非特异性发热、炎症反应，甚至导致转染细胞大面积毒性凋亡，从而彻底掩盖或破坏 DNA 疫苗的真实免疫效果。

2. 哺乳动物细胞（如 BHK-21 / HEK-21）的体外效能验证转染操作

在进行活体动物免疫前，必须先在体外贴壁细胞系（经典靶向为仓鼠肾细胞 BHK-21 或人肾上皮细胞 HEK-293T）中验证 pHFMDHZ-A 是否能够成功转录并高效表达出正确的 FMDV 抗原蛋白。

1. 铺板与细胞状态质控：

   转染前一天，将 BHK-21 细胞接种于 6 孔板中，使用含有 10% 优质胎牛血清的高糖 DMEM 完全培养基培养，待转染当天的细胞汇合度（Confluency）达到 70% - 80% 且处于对数生长最旺盛期。

2. 重组转染复合物配制（以脂质体 Lipofectamine 3000 为例）：

   • A管：吸取 125 $\mu$L 无血清 Opti-MEM 培养基，加入 2.5 - 4.0 $\mu$g 的去内毒素 pHFMDHZ-A 质粒 DNA，再加入 5 $\mu$L P3000 试剂，轻柔混匀。

   • B管：吸取 125 $\mu$L 无血清 Opti-MEM 培养基，加入 5 - 7.5 $\mu$L Lipofectamine 3000 转染试剂，轻柔混匀。

   • 复合孵育：将 A 管溶液全量倒入 B 管中，极其轻柔地吹打 2 次，室温下静置孵育 10 - 15 分钟，使其充分包裹组装成带正电荷的纳米级脂质体-DNA 复合物。

3. 加样与温和转染：

   • 将 250 $\mu$L 的复合物均匀逐滴滴加到长有 BHK-21 细胞的 6 孔板孔中，十字摇匀。

   • 放入 37 ℃、5% $CO_2$ 的无菌孵箱中。转染 4 - 6 小时后，为了最大化减轻转染试剂对细胞膜的剪切毒性，建议全量更换为新鲜的含 2% FBS 的 DMEM 维持培养基，继续暗培养 24 - 48 小时。

3. FMDV 抗原体外表达的检测与质量评估

转染 48 小时后，收集细胞样品以确证重组抗原的合成质量：

• 胞内表达与空间构象验证（免疫荧光间接法 IFA）：

  吸除培养基，用 PBS 洗涤细胞 2 次，使用 4% 对聚甲醛固定细胞 15 分钟。使用 0.1% Triton X-100 透膜后，加入特异性的抗 FMDV-A 型 VP1 单克隆抗体（或偶蹄动物康复期阳性血清）作为一抗，4 ℃ 孵育过夜。次日洗净后加入带有荧光标记（如 FITC，发射绿光）的二抗。在荧光显微镜下观察，若胞质内暴射出强烈的点状或弥漫性绿色荧光，证实 pHFMDHZ-A 具备完美的体外转录与正确的空间折叠表型。

• 分子量与定量检测（Western Blot）：

  使用 RIPA 裂解液收集细胞总蛋白，进行 SDS-PAGE 电泳并转移至 PVDF 膜上。利用特异性抗体进行显色，确证在预期分子量位置（如单体 VP1 约 24-26 kDa，或多表位融合肽对应分子量）出现清晰、均一、无无杂带的特定目标条带。

4. 动物活体（In vivo）免疫注射与长期储存标准

1. 肌肉注射免疫规范：

   体外质控达标后，将去内毒素的 pHFMDHZ-A 质粒用无菌生理盐水（PBS）稀释至工作浓度（如 500 $\mu$g - 1000 $\mu$g / 剂）。选择健康、经检测 FMDV 母源抗体阴性的实验偶蹄动物（如小口径 Beagle 犬作为安全毒性模型，或直接用于靶向幼猪、羊）。于动物后肢股四头肌或颈部进行深部肌肉注射（Intramuscular injection）。根据免疫策略，通常在第 0 周进行初免（Prime），第 3-4 周进行相同剂量的加强免疫（Boost），并在各个节点采血分离血清，进行液相阻断 ELISA（LPBE）或微量中和试验，评估抗体阳转率。

2. 质粒长期保存标准：

   • 短期存放：纯化好的高纯度 pHFMDHZ-A 质粒溶解于无菌 TE 缓冲液或超纯水中，4 ℃ 下可稳定存放 2-3 个月。

   • 长期锁死存放：分装成小体积（避免反复冻融），置于 -20 ℃ 或 -80 ℃ 超低温冰箱中锁死保存。在无菌且避免核酸酶污染的前提下，DNA 质粒在超低温下可稳定保存数年而其生物学超螺旋结构（Supercoiled form）和转染活性不发生降解。

Part 2 English Section

I General Information and Molecular Biological Background

• Vector Name: pHFMDHZ-A.

• Vector Classification: Mammalian 真核 expression vehicle / Recombinant poly-epitope DNA vaccine framework targeting Foot-and-Mouth Disease Virus (FMDV).

• Plasmid Size Scale: Approximately 5.5 - 6.2 kb (subject to minor variations configured to specific regional FMDV serotype antigens or length variants of the $VP1$ gene sequence).

• Backbone Origin and Veterinary Virology Context:

  The pHFMDHZ-A expression vector stands as a highly specialized genetic platform optimized for veterinary virology, livestock infectious disease counter-measures, and synthetic biology vaccine development. Its baseline framework is standardly constructed upon a robust mammalian expression engine (typically derived from classic optimized elements like the pcDNA or regulatory-approved pVAX1 DNA vaccine base backbones), precision-engineered to drive high-capacity expression of neutralizable antigens representing Foot-and-Mouth Disease Virus (FMDV) Serotype A (or engineered multivalent combination configurations).

  Traditional inactivated FMDV vaccines pose substantial biosecurity risks, including potential viral leakage during industrial manufacturing, low thermal stability, and an inability to distinguish vaccinated animals from naturally infected herds (lacking DIVA capability). The pHFMDHZ-A recombinant construct bypasses these constraints by delivering the targeted DNA directly into the skeletal muscle or dendritic cells of cloven-hoofed hosts (e.g., swine, cattle, sheep). This direct delivery prompts in vivo transcription and translation of targeted structural proteins (such as the envelope determinant $VP1$ or interconnected multi-epitope string domains), activating both robust humoral and cell-mediated immune responses. It serves as a gold-standard vehicle for evaluating nucleic acid therapeutics and designing prime-boost viral clearance strategies.

• Core Cis-Acting Elements and Map Characterization:

  • Human Cytomegalovirus Immediate-Early Promoter (CMV Promoter): Forces aggressive, transcription-factor independent mRNA synthesis of the downstream FMDV antigen payload inside mammalian structural muscle arrays and antigen-presenting cell environments.

  • FMDV Serotype A Antigen Cassette: The Multiple Cloning Site (MCS) is standardly loaded with (or engineered to accept) core immunogenic matrices derived from Serotype A isolates. This configuration standardly targets the highly variable G-H loop region of the $VP1$ protein, containing principal neutralizable B-cell epitopes linked sequentially with localized helper T-cell motifs.

  • High-Efficiency Eukaryotic Translational Machinery: Outfitted with a highly optimized Kozak consensus sequence immediately preceding the translation initiation codon to ensure precise ribosome docking, paired with a downstream Bovine Growth Hormone Polyadenylation Signal (BGH polyA) to augment transcription transcript stability and functional half-life within host tissues.

  • E. coli Propagation Assembly (Strict Regulatory Standard Alignment): Formulated with a standard pUC replication origin and a functional Kanamycin resistance gene ($Kan^R$). The integration of an Ampicillin marker is strictly avoided to comply with international regulatory mandates (FDA and WOAH) that prohibit beta-lactam selection markers in livestock DNA vaccine configurations. This design enables high-density industrial fermentation and high-purity vector isolation within Escherichia coli validation systems.

II Strategic Research Value and Veterinary Translational Applications

The pHFMDHZ-A platform serves as a critical preclinical blueprint for evaluating innovative veterinary biologics and exploring anti-viral defense networks:

1. Preclinical Profiling of Serotype-Specific Livestock DNA Vaccines:

   By injecting pHFMDHZ-A directly via intramuscular delivery or high-velocity gene gun platforms into targeted livestock models (e.g., swine or cattle), host structural arrays internalize the vector. The host cells subsequently process and present the synthesized FMDV antigen complexes to T and B lymphocytes. Measuring neutralizing antibody titers and monitoring targeted cytokine release (such as IFN-$\gamma$) provides a clear assessment of real-time protection efficiency against viral challenge.

2. Design Arrays for Poly-Epitope Concatenation and Molecular Adjuvants:

   Investigators standardly exploit the multi-cloning configuration to assemble chimeric expressions fusing targeted FMDV structural segments in tandem with molecular host adjuvants (e.g., porcine or bovine IL-2, IL-6, or GM-CSF). This integrated design overcomes the low immunogenicity limitations typical of standard legacy naked DNA vaccines, significantly increasing IgG antibody titers and systemic cellular memory responses.

3. Reverse Genetics and In Vitro Assembly of Virus-Like Particles (VLPs):

   Co-delivering the baseline structural proteins of FMDV ($VP0$, $VP3$, $VP1$) using pHFMDHZ-A derived multi-expression systems into continuous mammalian cell lines (e.g., BHK-21) enables the intracellular self-assembly of empty Virus-Like Particles (VLPs). These macromolecular arrays accurately mimic the native spatial conformation of the wild-type viral capsid but lack infectious viral nucleic acids, establishing a safe, non-replicative sub-unit architecture that supports accurate DIVA diagnostics.

III Laboratory Propagation, Endotoxin-Free Extraction, Transfection, and Immunological Validation Protocols

1. High-Density E. coli Fermentation and Endotoxin-Free Vector Processing

• Transformation Sequence: Introduce the circular pHFMDHZ-A vector into standard high-yield cloning E. coli cells (e.g., DH5$\alpha$ or JM109 competent arrays). Uniformly spread the transformation mixture onto solid selective LB agar plates supplemented with 50 $\mu$g/mL Kanamycin and incubate at 37 °C overnight.

• Endotoxin-Free Vector Isolation (Critical Safety Metric):

  Because this vector is intended for direct in vivo animal inoculations or sensitive primary cell transfections, standard industrial miniprep extraction mechanics are insufficient. Investigators must use specialized Endotoxin-Free Plasmid Maxiprep kits. The purified vaccine-grade DNA preparation must achieve a concentration of $\ge 1.0\text{ mg/mL}$, a clean purity index ($OD_{260}/OD_{280} = 1.80 - 1.90$), and an endotoxin payload threshold strictly beneath 0.1 EU/$\mu$g. Elevated endotoxin contamination triggers severe non-specific inflammatory shock, systemic pyrexia, and localized cellular apoptosis in recipient animals, compromising the validity of the vaccine evaluation.

2. In Vitro Validation via High-Efficiency Transfection of BHK-21 Cell Lines

Before initializing large-scale in vivo animal trials, the transcriptional fidelity and translation efficiency of pHFMDHZ-A must be verified in vitro using continuous susceptible cell lines, such as Baby Hamster Kidney cells (BHK-21) or human embryonic kidney lines (HEK-293T).

1. Monolayer Seeding and Quality Metrics:

   Seeding BHK-21 cells into 6-well plate configurations 24 hours prior to transfection using high-glucose DMEM complete medium fortified with 10% premium FBS. The cell layer must reach 70% - 80% confluency and remain in log-phase growth at the time of transfection.

2. Formulating Recombinant Transfection Complexes (Lipofectamine 3000 Protocol):

   • Tube A: Combine 125 $\mu$L of serum-free Opti-MEM reduced-serum matrix with 2.5 - 4.0 $\mu$g of endotoxin-free pHFMDHZ-A plasmid DNA; add 5 $\mu$L of P3000 reagent and mix gently.

   • Tube B: Combine 125 $\mu$L of serum-free Opti-MEM matrix with 5 - 7.5 $\mu$L of Lipofectamine 3000 transfection reagent and mix gently.

   • Complex Assembly: Transfer the contents of Tube A directly into Tube B. Mix using gentle pipetting and incubate statically at room temperature for 10 - 15 minutes to permit the assembly of cationic lipid-DNA liposomal nanoparticles.

3. Transfection Execution:

   • Add the 250 $\mu$L liposomal complex solution dropwise across the BHK-21 monolayer and rock the plate in a cross pattern to ensure even distribution.

   • Return the plates to the sterile incubator calibrated to 37 °C with 5% $CO_2$. To minimize liposomal membrane toxicity, aspirate the transfection matrix 4 - 6 hours post-application and replace with fresh maintenance DMEM supplemented with 2% FBS. Incubate for an additional 24 - 48 hours.

3. In Vitro FMDV Antigen Tracking and Expression Metrics

Following 48 hours of incubation, harvest the cell matrices to evaluate recombinant protein expression:

• Intracellular Spatial Mapping (Indirect Immunofluorescence Assay - IFA):

  Aspirate the growth fluid, wash twice with sterile PBS, and fix the cell sheet with 4% paraformaldehyde for 15 minutes. Permeabilize cell membranes using 0.1% Triton X-100, then apply an anti-FMDV Serotype A VP1 monoclonal antibody (or hyper-immune convalescent livestock serum) as the primary detection antibody, incubating at 4 °C overnight. Wash thoroughly, then apply a fluorophore-conjugated secondary detection antibody (e.g., FITC, emitting green light). Under a fluorescence microscope, robust punctate or diffuse green fluorescence localized within the cytoplasm confirms target antigen expression and proper protein folding.

• Molecular Weight Verification (Western Blotting Array):

  Lyse the monolayers using RIPA lysis buffer and isolate total cellular protein. Resolve the samples via SDS-PAGE and transfer to a PVDF membrane. Probing with the specific primary antibody should reveal a distinct band at the expected molecular weight (e.g., monomeric VP1 clocks around 24-26 kDa), confirming a clean expression profile free of non-specific degradation products.

4. In Vivo Livestock Inoculation Steps and Cryopreservation Parameters

1. Intramuscular Immunization Protocol:

   Following successful in vitro validation, dilute the endotoxin-free pHFMDHZ-A plasmid matrix in sterile saline (PBS) to a target working dose (typically 500 $\mu$g - 1000 $\mu$g per injection). Select healthy, FMDV-maternal antibody-negative target livestock (such as young swine or sheep). Deliver the dose via deep intramuscular injection into the quadriceps or the neck muscle layers. Execute a prime-boost schedule, applying an identical booster dose 3 - 4 weeks post-priming. Collect regular blood samples to isolate serum and monitor antibody seroconversion metrics via liquid-blocking ELISA (LPBE) or micro-neutralization assays.

2. Long-Term Vector Cryopreservation Standards:

   • Short-Term Maintenance: Store purified high-purity pHFMDHZ-A plasmid dissolved in sterile TE buffer or ultra-pure water at 4 °C for 2 - 3 months.

   • Long-Term Cryopreservation: Aliquot the plasmid into small single-use working volumes to prevent repeated freeze-thaw degradation. Store the vials inside an ultra-low freezer calibrated to -20 °C or -80 °C. Under sterile conditions free of nucleating contamination, the supercoiled plasmid structure and functional transfection velocity remain fully stable for several years.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址http://www.biovector.net